These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

529 related items for PubMed ID: 28160567

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
    He T, Surdez D, Rantala JK, Haapa-Paananen S, Ban J, Kauer M, Tomazou E, Fey V, Alonso J, Kovar H, Delattre O, Iljin K.
    Gene; 2017 Jan 05; 596():137-146. PubMed ID: 27760381
    [Abstract] [Full Text] [Related]

  • 5. EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.
    Cidre-Aranaz F, Grünewald TG, Surdez D, García-García L, Carlos Lázaro J, Kirchner T, González-González L, Sastre A, García-Miguel P, López-Pérez SE, Monzón S, Delattre O, Alonso J.
    Oncogene; 2017 Feb 09; 36(6):766-776. PubMed ID: 27375017
    [Abstract] [Full Text] [Related]

  • 6. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
    Tang SW, Bilke S, Cao L, Murai J, Sousa FG, Yamade M, Rajapakse V, Varma S, Helman LJ, Khan J, Meltzer PS, Pommier Y.
    Clin Cancer Res; 2015 Sep 15; 21(18):4184-93. PubMed ID: 25779942
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
    Theisen ER, Pishas KI, Saund RS, Lessnick SL.
    Oncotarget; 2016 Apr 05; 7(14):17616-30. PubMed ID: 26848860
    [Abstract] [Full Text] [Related]

  • 8. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T, Giorgi C, Schmidt O, Calzada-Wack J, Neff F, Buch T, Niggli FK, Schäfer BW, Burdach S, Richter GH.
    Oncotarget; 2016 Jan 12; 7(2):1451-63. PubMed ID: 26623725
    [Abstract] [Full Text] [Related]

  • 9. Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue.
    Gierisch ME, Pfistner F, Lopez-Garcia LA, Harder L, Schäfer BW, Niggli FK.
    J Biol Chem; 2016 Dec 23; 291(52):26922-26933. PubMed ID: 27875302
    [Abstract] [Full Text] [Related]

  • 10. Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis.
    Ma Y, Baltezor M, Rajewski L, Crow J, Samuel G, Staggs VS, Chastain KM, Toretsky JA, Weir SJ, Godwin AK.
    J Mol Med (Berl); 2019 Jul 23; 97(7):957-972. PubMed ID: 31025088
    [Abstract] [Full Text] [Related]

  • 11. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
    Kovar H.
    Expert Opin Ther Targets; 2014 Nov 23; 18(11):1315-28. PubMed ID: 25162919
    [Abstract] [Full Text] [Related]

  • 12. Ewing sarcoma EWS protein regulates midzone formation by recruiting Aurora B kinase to the midzone.
    Park H, Turkalo TK, Nelson K, Folmsbee SS, Robb C, Roper B, Azuma M.
    Cell Cycle; 2014 Nov 23; 13(15):2391-9. PubMed ID: 25483190
    [Abstract] [Full Text] [Related]

  • 13. Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma.
    Niedan S, Kauer M, Aryee DN, Kofler R, Schwentner R, Meier A, Pötschger U, Kontny U, Kovar H.
    Oncogene; 2014 Jul 24; 33(30):3927-38. PubMed ID: 23995784
    [Abstract] [Full Text] [Related]

  • 14. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN, Tang N, Fleming JT, Ma Y, Guo Y, Borinstein SC, Chiang C, Wang J.
    Oncotarget; 2016 Jul 12; 7(28):43504-43517. PubMed ID: 27259270
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G2-M cell cycle arrest and enhanced vincristine sensitivity in Ewing's sarcoma.
    Zöllner SK, Selvanathan SP, Graham GT, Commins RMT, Hong SH, Moseley E, Parks S, Haladyna JN, Erkizan HV, Dirksen U, Hogarty MD, Üren A, Toretsky JA.
    Sci Signal; 2017 Oct 03; 10(499):. PubMed ID: 28974650
    [Abstract] [Full Text] [Related]

  • 16. Ablation of EWS-FLI1 by USP9X inhibition suppresses cancer cell growth in Ewing sarcoma.
    Wang S, Huo X, Yang Y, Mo Y, Kollipara RK, Kittler R.
    Cancer Lett; 2023 Jan 01; 552():215984. PubMed ID: 36330954
    [Abstract] [Full Text] [Related]

  • 17. EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma.
    Shimizu R, Tanaka M, Tsutsumi S, Aburatani H, Yamazaki Y, Homme M, Kitagawa Y, Nakamura T.
    Cancer Sci; 2018 Sep 01; 109(9):2907-2918. PubMed ID: 29945296
    [Abstract] [Full Text] [Related]

  • 18. EWS-FLI1 reprograms the metabolism of Ewing sarcoma cells via positive regulation of glutamine import and serine-glycine biosynthesis.
    Sen N, Cross AM, Lorenzi PL, Khan J, Gryder BE, Kim S, Caplen NJ.
    Mol Carcinog; 2018 Oct 01; 57(10):1342-1357. PubMed ID: 29873416
    [Abstract] [Full Text] [Related]

  • 19. EWS-FLI1 and Menin Converge to Regulate ATF4 Activity in Ewing Sarcoma.
    Jiménez JA, Apfelbaum AA, Hawkins AG, Svoboda LK, Kumar A, Ruiz RO, Garcia AX, Haarer E, Nwosu ZC, Bradin J, Purohit T, Chen D, Cierpicki T, Grembecka J, Lyssiotis CA, Lawlor ER.
    Mol Cancer Res; 2021 Jul 01; 19(7):1182-1195. PubMed ID: 33741715
    [Abstract] [Full Text] [Related]

  • 20. EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance.
    Robin TP, Smith A, McKinsey E, Reaves L, Jedlicka P, Ford HL.
    Mol Cancer Res; 2012 Aug 01; 10(8):1098-108. PubMed ID: 22723308
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.